

Changes in PrCreon Minimicrospheres® 25 (pancreatin) capsule shell

Viatriis is committed to providing access to safe and reliable medicines to our patients.

We would like to inform you of the change in size of Creon 25 capsules to allow for optimization in the manufacturing process. As a result, the length of the capsule has increased from 21.7mm to 24.2mm. There is no change in the diameter of the capsule.

In addition, Titanium Dioxide (E171), a food additive has also been removed from the new batches of Creon 25. The removal of this component will not affect the quality, safety, or efficacy of the treatment.

Creon 25 Lot 64165, was the first batch released in Canada on December 19, 2023 with these changes.

If you have any questions, please contact Viatriis Customer Service at 1-800-575-1379 or email customerservice.ca@viatriis.com. For medical information requests, please call 1-877-446-3679.

Creon Minimicrospheres® (pancreatin) is indicated in pediatric and adult patients for: the treatment of pancreatic exocrine insufficiency attributed to cystic fibrosis, chronic pancreatitis, or any other medically defined pancreatic disease that might require pancreatic enzyme therapy. Consult the Product Monograph at <https://healthproducts.canada.ca/dpd-bdpp/index-eng.jsp> for more information about conditions of clinical use, contraindications, warnings, precautions, adverse reactions, interactions and dosing. The Product Monograph is also available by calling BGP Pharma ULC at 1-877-446-3679.

Yours Sincerely,

Viatriis Canada

Adverse events should be reported immediately to Viatriis by phone 1-877-446-3679 or e-mail PV.Canada@viatriis.com or to Health Canada by visiting the web page on [Adverse Reaction Reporting](#) or by calling toll-free at 1-866-234-2345.

CRE-2024-0071B - MR2024